NCT04910685 2026-03-10(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisBlueprint Medicines CorporationPhase 2/3 Recruiting534 enrolled
NCT05362773 2026-01-13A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesMacroGenicsPhase 1 Recruiting130 enrolled
NCT04655118 2024-05-10Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisTelios Pharma, Inc.Phase 2 Recruiting121 enrolled